Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » Chemotherapy-induced Neuropathy in Childhood Cancer Survivors
    ABSTRACT & COMMENTARY

    Chemotherapy-induced Neuropathy in Childhood Cancer Survivors

    July 1, 2018
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share

    Related Articles

    Chemotherapy-Induced Neuropathy in Pediatrics

    Reproductive and Sexual Function in Long-term Ovarian Cancer Survivors after Platinum-based Chemotherapy

    Risk of Cancer Among Offspring of Childhood-Cancer Survivors

    Related Products

    Take Me Out of the Ball Game: Acute Management and Long-term Consequences of Concussion in Childhood

    Chemotherapy in Latinas: Stress Management Needs and Techniques

    Keywords

    Chemotherapy

    Neuropathy

    childhood

    chemotherapy-induced

    By Michael Rubin, MD

    Professor of Clinical Neurology, Weill Cornell Medical College

    Dr. Rubin reports no financial relationships relevant to this field of study.

    SYNOPSIS: Long-term symptoms and disability from chemotherapy-induced peripheral neuropathy occur in more than half of childhood survivors of cancer, with vinca alkaloids and platinum agents implicated most often.

    SOURCE: Kandula T, Farrar MA, Cohn RJ, et al. Chemotherapy-induced peripheral neuropathy in long-term survivors of childhood cancer: Clinical, neurophysiological, functional, and patient-reported outcomes. JAMA Neurol 2018; May 14. doi:10.1001/jamaneurol.2018.0963. [Epub ahead of print].

    Survival for five years or more after a diagnosis of childhood cancer is associated with a normal life span and, given an 80% survival rate for many childhood and adolescent cancers, long-term effects of cancer therapy can result in significant long-term morbidity. What is the disease burden and functional effect of surviving childhood cancer but suffering chemotherapy-induced peripheral neuropathy in the long term?

    Kandula et al recruited cancer survivors who had received chemotherapy for extracranial malignancy prior to the age of 17 years between April 2015 and December 2016 from the Long-Term Follow-Up Clinic at the Kids Cancer Centre at Sydney Children’s Hospital in Australia for this cross-sectional observational study. Exclusionary criteria encompassed other diseases associated with neuropathy, including diabetes, critical illness, and hereditary neuropathic or developmental disorders. Neuropathy assessment comprised nerve conduction studies, the pediatric-modified Total Neuropathy Score, the Movement Assessment Battery, the Pediatric Quality of Life Inventory Generic Core Scales, and the Pediatric Outcomes Data Collection Instrument, which, for participants 17 years or older, included Von Frey monofilaments, grating orientation task, grooved peg board task for functional measures, the European Organization for Research and Treatment of Cancer quality-of-life questionnaire, and the chemotherapy-induced peripheral neuropathy
    questionnaire. Statistical analysis involved two-tailed t tests and Mann-Whitney U tests for nonparametric subgroup analyses, χ2 tests for nominal data, one-way analysis of variance for multiple groups, and Pearson or Spearman correlations, with a P value < 0.05 considered significant.

    Among 169 patients who met inclusion criteria, 48 declined participation or were unreachable, leaving a cohort of 121 long-term childhood cancer survivors to be studied, of whom 53.7% were male, 46.3% were female, with a median age at diagnosis and chemotherapy of four years, and a median age at evaluation of 16 years, which was a median of 8.5 years after completing chemotherapy. Leukemia comprised the largest group (52.9%), followed by solid tumors (29.8%) and lymphoma (14%). Vinca alkaloids were the most common form of chemotherapy (71.1%), among whom 4.1% received multiple vinca alkaloids. Platinum agents were used in 16.5%, including cisplatin or carboplatin (5.8% each), with 5% who received both. Both platinum agents and vinca alkaloids were given in 10.7%, and radiotherapy was given to 43.8% overall.

    Peripheral neuropathy was seen in 50.5% of patients treated with neurotoxic chemotherapy, predominantly associated with sensory axonal neuropathy in the legs, accompanied by impaired manual dexterity, distal sensation, and balance, and by patient-reported reduced global quality of life and physical functioning, with cisplatin more frequently causing long-term neurotoxicity than vinca alkaloids. Peripheral neuropathy is common in long-term childhood cancer survivors.

    COMMENTARY

    No effective pharmacologic intervention is available to prevent chemotherapy-induced peripheral neuropathy, and no consensus exists to evaluate its incidence or severity. Whereas very few conventional, neuroprotection, drug-based trials are available that address this problem, there are an increasing number of non-conventional trials that do, using physical treatments including magnetic field therapy, diathermy, photobiomodulation, or electroacupuncture, alone or in combination with physical therapy. None have shown evidence of clinical effectiveness, although subjective relief is reported occasionally. New methodological approaches are necessary. Nitro-oxidative stress resulting from neuronal mitochondrial dysfunction, representing final common pathways in the development of chemotherapy-induced polyneuropathy, may be such an avenue, using drugs such as metformin or interleukin 10. Hopefully, future research will bridge the gap.1,2

    REFERENCE

    1. Ma J, Kavelaars A, Dougherty PM, Heijnen CJ. Beyond symptomatic relief for chemotherapy-induced peripheral neuropathy: Targeting the source. Cancer 2018;124:2289-2298.
    2. Cavaletti G, Marmiroli P. Pharmacotherapy options for managing chemotherapy-induced peripheral neurotoxicity. Expert Opin Pharmacother 2018;19:113-121.

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    Neurology Alert

    View PDF
    Neurology Alert (Vol. 37, No. 11) - July 2018
    July 1, 2018

    Table Of Contents

    Predicting the Risk of Late-onset Alzheimer’s Disease and Dementia Based on Common Genetic Variants

    Ufmylation and Brain Development: Effects of Gene Mutations

    Cannabidiol: Does It Help in Drug-resistant Epileptic Encephalopathies?

    Chemotherapy-induced Neuropathy in Childhood Cancer Survivors

    Prodromal Symptoms Predict the Onset of α-Synucleinopathies

    Dual Antiplatelet Therapy for Minor Ischemic Stroke or TIA

    Tenecteplase vs. Alteplase for Ischemic Stroke

    Begin Test

    Buy this Issue/Course

    Financial Disclosure: Neurology Alert’s Editor in Chief Matthew Fink, MD; Peer Reviewer M. Flint Beal, MD; Executive Editor Leslie Coplin; Editor Jonathan Springston; and Editorial Group Manager Terrey L. Hatcher report no financial relationships relevant to this field of study.

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421 x 2

    International +1-404-262-5476 x 2

    Accounts Receivable

    1-800-688-2421 x 3
    ReliasMedia_AR@reliasmedia.com

    Sales

    1-800-688-2421 x 1

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2022 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing